Avilés A, García E L, Guzmán R, Talavera A, Poot J J, Díaz-Maqueo J C
Departamento de Hematologia, Hospital de Oncologia, Centro Médico Nacional, IMSS, México, D.F.
Rev Invest Clin. 1991 Apr-Jun;43(2):146-50.
Forty-three patients with advanced malignant lymphoma resistant to previous chemotherapy were randomized in two groups: one received a high dose versus a low-dose cytosine arabinoside, in combination with dexamethasone and cisplatinum. Ten of 24 patients (41%) in the low-dose regimen achieved response: six complete remission (CR) and four partial remission (PR), compared with 5 of 19 (30%) (three CR and two PR). Survival was better in the low dose regimen: 39 versus 23 weeks. Toxicity was most frequent and severe in the high dose schedule. These results suggests that the use of cytosine arabinoside and cisplatinum is useful in the treatment of refractory lymphoma, and that the low-dose would be a better alternative than a high dose.
43例对先前化疗耐药的晚期恶性淋巴瘤患者被随机分为两组：一组接受高剂量与低剂量阿糖胞苷，并联合地塞米松和顺铂。低剂量方案组的24例患者中有10例（41%）获得缓解：6例完全缓解（CR）和4例部分缓解（PR），而高剂量方案组19例中有5例（30%）（3例CR和2例PR）。低剂量方案组的生存期更长：39周对比23周。高剂量方案的毒性最常见且严重。这些结果表明，阿糖胞苷和顺铂在难治性淋巴瘤的治疗中是有效的，并且低剂量比高剂量是更好的选择。
